Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety,
tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2
dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Age: 18 years - 66+
Gender: All
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety and preliminary efficacy of
CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s)
in participants with advanced or metastatic solid tumors.
Age: 18 years - 66+
Gender: All
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study
designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with
advanced cancers that harbor HER2 alterations.
Age: 18 years - 66+
Gender: All
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel,
oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for
controlling the growth and/or spreading of the disease in patients with gastric or
gastroesop...
Age: 18 years - 66+
Gender: All
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study
to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080
monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1
inhibitor), cetuxim...
Age: 18 years - 66+
Gender: All
